Counseling and Management of R&D Activities in Immunotherapy and Vaccines
Explore & Develop
New R&D Territories in
Immunotherapy & Prevention of
Cancer, Immune Disorders, and Infectious Diseases
Contact details: Rémi Palmantier, PhD, President & Founder of ImmThera Consulting SAS, France.email: remip@immthera.com - Linkedin profile
IMMTHERA CONSULTING
HELPS YOU TO BUILD ON THE COMPLEX
SCIENTIFIC AND R&D EQUATION
OF IMMUNOTHERAPY SUCCESSES & FUTURE PROMISES
The time has come to a new wave of immune-based innovative products
for the treatment of cancer and chronic disorders
-----------------------------------------------------------
A turning point in cancer treatment in 2011 with the first FDA approved immune checkpoint inhibitor and followers (ie. anti-PD(L)-1, BiTEs & CAR-T cells) in multiple indications
+
The successful achievements of multiple biologics & drugs targeting immune regulation to better control chronic autoimmune/allergic/inflammatory diseases
+
An outstanding history of success of the prophylactic vaccines and the advent of modern vaccinology
+
An extensive know-how & lessons learned from the many unproductive attempts to develop therapeutic immunization
(cancer, autoimmunity/allergy, virus)
+
A much deeper understanding of cellular and molecular immunology, pathophysiology, and homeostasis (innate & adaptive immunity, immune tolerance, Immune Checkpoint Blockade, biomarkers, tumor neoantigens, disease-related antigens...)
+
The continual innovation and improvement of technologies to boost, regulate, and monitor the immunity
(eg. delivery platforms, immunomodulators, translational research)
+
Accessibility to a broader choice of preclinical models and key technologies, eg. humanized mice, organoids, targeting, Big data, WES, NGS, single cell analysis, gene editing …
+
A changing environment, ie. regulatory constraints & opportunities, multiplication of CROs...
=
The advent of immuno-oncology as a specific, measurable, actionable, and realistic tool for treatment
A surge of new biologics & targeted therapies getting closer to the root-cause of the auto-immune and allergic processes
A broad variety of highly promising and risky new projects, targets & technical opportunities based on immune-mediated MoA
IMMTHERA SOLUTIONS
> MAKE THE LINKS & HELP TO FIND THE RIGHT PATH
> DEVELOP THE RIGHT PROJECT THE RIGHT WAY
> BUILD R&D STRATEGY PLAN
> IMPLEMENT & MANAGE PROJECTS FROM DISCOVERY TO CLINICAL DEVELOPMENT STAGE